Clinical Trial

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-05
notable Trial sites expanded: 0 -> 3 locations 2026-08-05
minor Completion pushed: 2030-02 -> 2030-08 2026-06-24
Trial Details
NCT Number NCT07656415
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Sickle Cell Disease
Enrollment 159 participants
Start Date 2026-07-21
Primary Completion 2029-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-04